PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Combination Product: Alirocumab and Cemiplimab
- Registration Number
- NCT05553834
- Lead Sponsor
- Duke University
- Brief Summary
PCSK9 mediates immune checkpoint blockade resistance by downregulating tumor cell surface MHC class 1 molecules. This study will evaluate if combining the anti-PCSK9 antibody alirocumab with the anti-PD-1 antibody cemiplimab can generate anti-tumor activity and clinical responses in patients with metastatic lung cancer who have progressed on first line immune checkpoint blockade therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 60
- Histologically documented recurrent and/or metastatic non-small cell lung cancer
- Progression after prior PD-1 directed therapy (as monotherapy or in combination with chemotherapy and/or anti-CTLA4, or anti-VEGF agents) - defined as investigator assessed progression from prior treatment
- If molecularly altered NSCLC including EGFR, ALK, ROS1, MET exon 14, RET, BRAF, NTRK, progression on prior targeted therapy is required
- Measurable disease by RECIST 1.1
- ECOG Performance Status 0 or 1
- Signed written informed consent
- Minimum of 4 weeks from any other experimental anti-cancer therapies or prior PD-1 treatment
- Meet all the laboratory criteria per protocol
- Prior treatment with PCSK9 inhibitors
- Cardiac issues including MI, uncontrolled arrhythmia, symptomatic angina pectoris, active ischemia, or cardiac failure not controlled by medications.
- Uncontrolled diabetes mellitus, defined as HbA1c > 10
- Major surgery less than 4 weeks prior to study enrollment
- Another malignant condition diagnosed within 3 years of study enrollment
- Intolerance to prior PD-1/L1 treatment including discontinuation for severe or recurrent severe toxicity (including myocarditis or other myocardiotoxity, encephalitis, colitis, diarrhea, pancreatitis, hypo/hyperthyroidism, hypopituitarism, adrenal insufficiency, rash, autonomic neuropathy, myasthenia gravis, Guillain-Barre, myositis/polymyositis, hepatitis, Type 1 Diabetes, thrombocytopenia) or developed an immune checkpoint blockade related immune adverse event that was refractory to steroids and required additional systemic immunosuppressive medication.
- Known history of HIV seropositivity or known acquired immunodeficiency syndrome (AIDS)
- Additional exclusion criterion as per listed in the protocol
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Alirocumab and Cemiplimab Alirocumab and Cemiplimab Combination of anti-PCSK9 antibody alirocumab with the anti-PD-1 antibody cemiplimab
- Primary Outcome Measures
Name Time Method Response rate associated with combination of alirocumab and cemiplimab Day 1 of treatment until the date of first documented progression or date of death, whichever comes first, assessed up to 110 weeks per RECIST 1.1 Ascertain the response rate associated with alirocumab and cemiplimab, with 95% confidence intervals. Response rate is defined as the proportion of treated subjects with a complete or partial response per RECIST 1.1 criteria. All patients who receive at least one dose of alirocumab and cemiplimab will be considered for the primary outcome analysis
- Secondary Outcome Measures
Name Time Method Progression Free Survival Day 1 of treatment until the date of first documented progression or date of death, whichever comes first, assessed up to 110 weeks Progression Free Survival will be assessed utilizing RECIST 1.1 criteria
Overall survival Day 1 of treatment until death or off study due to any other reason whichever comes first, assessed up to 110 weeks Patients will be followed till death or off study due to any other reason
Safety and tolerability of the combination regimen Day 1 of treatment until 30 days post last dose Toxicity analysis will be performed on a continual basis following CTC V 5.0 criteria
Trial Locations
- Locations (2)
Moffitt Cancer Center
🇺🇸Tampa, Florida, United States
Duke University
🇺🇸Durham, North Carolina, United States